Enterprise Value
164.3M
Cash
45.93M
Avg Qtr Burn
-7.823M
Short % of Float
4.68%
Insider Ownership
4.42%
Institutional Own.
41.06%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OpRegen® (RPE Cells) Details Dry eye disease , Age-related macular degeneration | Phase 1/2 Data readout | |
VAC2 (Dendritic Cells) Details Non-small cell lung carcinoma, Lung cancer, Lung disease | Phase 1 Update | |
OPC1 (Oligodendrocytes) Details Spine disorder, Spinal cord injury | Phase 1 Update |